About TreeFrog Therapeutics
TreeFrog Therapeutics is a company based in Talence (France) founded in 2018 by Maxime Feyeux and Kevin Alessandri. TreeFrog Therapeutics has raised $84.25 million across 8 funding rounds from investors including European Investment Bank, Bpifrance and European Union. TreeFrog Therapeutics operates in a competitive market with competitors including Merck, Roivant Sciences, Gilead, Lilly and Vertex Pharmaceuticals, among others.
- Headquarter Talence, France
- Founders Maxime Feyeux, Kevin Alessandri
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$84.25 M (USD)
in 8 rounds
-
Latest Funding Round
$34.17 M (USD), Debt – Conventional
May 27, 2025
-
Investors
European Investment Bank
& 10 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of TreeFrog Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of TreeFrog Therapeutics
TreeFrog Therapeutics has successfully raised a total of $84.25M across 8 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $34.17 million completed in May 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in TreeFrog Therapeutics
TreeFrog Therapeutics has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include European Investment Bank, Bpifrance and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked | |
|
Venture capital fund focused on tech companies
|
Locked | Locked | Locked | |
|
Recapitalizations are targeted through private equity investments by the firm.
|
Locked | Locked | Locked |
Investor details for TreeFrog Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by TreeFrog Therapeutics
Investment portfolio details for TreeFrog Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - TreeFrog Therapeutics
Detailed financials for TreeFrog Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Treefrog Therapeutics Comparisons
Peer comparison for TreeFrog Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of TreeFrog Therapeutics
TreeFrog Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, Roivant Sciences, Gilead, Lilly and Vertex Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| Locked | Locked | Locked |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
|
|
| Locked | Locked | Locked |
Traditional pharmaceutical medicines are developed for multiple health fields.
|
|
| Locked | Locked | Locked |
Developer of drugs for the treatment of multiple disorders
|
|
| Locked | Locked | Locked |
Biopharmaceutical research and drug development are conducted globally by AbbVie.
|
Detailed competitors of TreeFrog Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Treefrog Therapeutics
Complete news archive for TreeFrog Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about TreeFrog Therapeutics
TreeFrog Therapeutics was founded in 2018 and raised its 1st funding round 1 year after it was founded.
TreeFrog Therapeutics is headquartered in Talence, France. It is registered at Talence, Nouvelle-aquitaine, France.
Maxime Feyeux is the current CEO of TreeFrog Therapeutics. They have also founded this company.
TreeFrog Therapeutics is a funded company, having raised a total of $84.25M across 8 funding rounds to date.
TreeFrog Therapeutics is developing stem cells and organoids using proprietary technology to enable the development of cell therapies. It enables the younger cells to mitigate mutational risks. They have developed organoids from pluripotent stem cells.
TreeFrog Therapeutics's top competitors include Merck, Roivant Sciences and AbbVie.
TreeFrog Therapeutics has 11 investors. Key investors include European Investment Bank, Bpifrance, European Union, EIC Fund, and XAnge.